Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

Stage IIIA triple-negative breast cancer with hypercalcemia from parathyroid adenoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

As of October 2025, evaluation for post-chemotherapy weakness showed no local breast cancer recurrence, no lymphadenopathy, and no bone metastases; hypercalcemia resolved after parathyroid adenoma removal while breast cancer care remained ongoing.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

PT3N0 triple-negative breast carcinosarcoma: surgery, EC chemotherapy, radiation, disease-free at 26 months

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast carcinosarcoma. INI1 was retained

She was clinically free of disease at her last follow-up in April 2025, 26 months after treatment completion; December 2024 mammography showed no suspicious changes.

PubMed CentralRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Triple-negative node-positive breast cancer with complete pathologic response and benign nodal nevi

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer; BRCA testing negative. Axillary melanocytic cells looked benign.

Pathology showed complete response in the breast, no residual breast carcinoma in the sampled specimen, and axillary nodal melanocytic proliferations interpreted as benign nodal nevi rather than metastatic melanoma or breast carcinoma.

PubMed CentralRead more →

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed CentralRead more →

Stage IIIB triple-negative breast cancer: complete response after LVAD-supported neoadjuvant immunotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 95%; nuclear grade 3, triple negative

As of July 2025, breast cancer remained in remission 2.5 years after mastectomy, after neoadjuvant paclitaxel/carboplatin/pembrolizumab, surgery, radiation, and 1 year of adjuvant pembrolizumab.

PubMed CentralRead more →

HER2-positive breast cancer with metastatic recurrence and complete response to T-DM1

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 IHC 3+ and hormone receptor-negative in primary and metastatic breast cancer; no liver metastases seen.

Metastatic Site: major pectoralis muscle, lung, broncho-hilar lymph…

After complete radiologic response on T-DM1, treatment was stopped after 22 months because of porto-sinusoidal vascular disorder. Seven months later, she remained asymptomatic and under surveillance with no signs of recurrent disease.

PubMed CentralRead more →

Severe Melioidosis During Chemotherapy for Metastatic Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

A 58-year-old woman with metastatic breast cancer developed life-threatening melioidosis and severe low blood counts after her sixth chemotherapy cycle, requiring intensive infection treatment.

PubMed CentralRead more →

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Triple-negative sebaceous carcinoma of the breast: no recurrence after multimodality treatment

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative sebaceous breast carcinoma; EMA-positive; Ki-67 50-60%; inherited breast/ovarian cancer testing negative for pathogenic variants.

As of May 2025, after surgery, adjuvant chemotherapy, and radiation, she had 5 years of follow-up with no evidence of neoplastic recurrence.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient StoryRead more →

Breast Cancer in a Woman Carrying Both BRCA1 and BRCA2 Mutations

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative, BRCA1 pathogenic variant, BRCA2 pathogenic variant

Remained free of recurrence 17 months after treatment.

PubMed CentralRead more →

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed CentralRead more →

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed CentralRead more →